Ariana Lebsa Weber *

Autora invitada por SIIC

O trabalho visa estabelecer dados epidemiológicos sobre melanoma em Florianópolis.

DIAGNÓSTICO; MELANOMA; MELANOMA/PATOLOGIA; NEOPLASIAS CUTÂNEAS

O perfil histopatológico do melanoma cutâneo neste estudo foi melanoma tipo extensivo superficial, invasivo, Breslow 1,25mm, com infiltrado inflamatório e margens livres.

*Ariana Lebsa Weber
describe para SIIC los aspectos relevantes de su trabajo
AVALIAÇÃO DE 496 LAUDOS ANATOMOPATOLÓGICOS DE MELANOMA DIAGNOSTICADOS NO MUNICÍPIO DE FLORIANÓPOLIS, SANTA CATARINA, BRASIL
Institución principal de la investigación
*Universidade Federal de Santa Catarina (UFSC), Santa Catarina, Brasil
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Sampaio SAP, Rivitti EA. Dermatologia. 2 ed. São Paulo: Artes Médicas; 2001. p.871-86.
2. Morton DL, Essner R, Kirkwood JM., Wollman RC. Malignant Melanoma. In: Holland JF, Frei E, Bast RC Jr, Pollock RE, Kufe DW, Weichselbaum RR, eds. Cancer Medicine. 6th ed. Ontário: Decker Inc; 2003. p. 2400.
3. Monzon J. CDKN2A mutations in multiple primary melanoma. N Engl J Med. 1998;338:879.
4. Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, et al. A natural history of melanoma and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer. 2002;94:3192.
5. Ross MH, Rowrell LJ. Histologia texto e atlas. 2nd ed. Baltimore: Panamericana; 1993.
6. Cotran R, Kumar V, Collins T. Robbins patologia estrutural e funcional. 6 ed. Rio de Janeiro. Guanabara Koogan; 2000.
7. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;182:572.
8. INCA [homepage]. 2005 Câncer de Pele Melanoma. [acesso 2005 ago 10]. Disponível em: http://www.inca.gov.br.
9. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin. 2003;53:5-26.
10. Katalinic A, Kunze U, Schafer T. Epidemiology of cuta neous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical sub types, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol. 2003;149:1200-6.
11. Wallon-Dumon G, Dreno B. The clinical diagnosis of melanoma. Presse Med. 2003;32:33-8.
12. Pinheiro AMC, Friedman H, Cabral ALSV, Rodrigues HA. Melanoma cutâneo: características clínicas, epidemiológicas e histopatológicas no Hospital Universitário de Brasília entre janeiro de 1994 e abril de 1999. An Bras Dermatol. 2003;78:179-86.
13. Lapa MS, Guedes KF, Schalch FO, Landman G. Melanomas malignos cutâneos tratados no Hospital de Cancer de São Paulo. Estudo retrospectivo para avaliação, fatores prognósticos e sobrevida. An Bras Dermatol. 2002;77:313-20.
14. Clemente C, Cook M, Ruiter D, Mihm MC. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol. 1991;22:313-9.
15. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19:3635-48.
16. Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1 mm thick). Cancer. 2004;100:433-4.
17. Scolyer RA, Thompson JF, Stretch JR, Sharma R, McCarthy SW. Pathology of melanocytic lesions: new, controversial, and clinically important issues. J Surg Oncol. 2004;86:200-11.
18. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in pacients with primary cutaneous melanoma: analysis of 3661 patients from a single center. Cancer. 2003;97:1488-98.
19. Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czemiechi B. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22:3668-76.
20. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Thin cutaneous malignant melanoma (< or = 1,5mm): identification of risk factors indicative of progression. Cancer. 1999;85:1067-76.
21. Veronese LA, Marques MEA. Critérios anatomopatoló gicos para melanoma maligno cutâneo: análise qualitativa de sua eficácia e revisão da literatura. J Bras Patol Med Lab. 2004;40:99-112.
22. Mckinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98:1223-31.
23. Balch CM, Soong SJ, Atkins M, Buzaid AC, Cascinelli N, Goit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54:131-49.
24. Edwood JM, Gallagher RP. Site distribution of malignant melanoma. Can Med Assoc J. 1983;128:1400.
25. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol. 2003;139:1620-4.
26. Lebwohl MG. Atlas de dermatologia e doenças sistêmicas. Rio de Janeiro: Revinter; 2000. p.190-8.
1. Sampaio SAP, Rivitti EA. Dermatologia. 2 ed. São Paulo: Artes Médicas; 2001. p.871-86.
2. Morton DL, Essner R, Kirkwood JM., Wollman RC. Malignant Melanoma. In: Holland JF, Frei E, Bast RC Jr, Pollock RE, Kufe DW, Weichselbaum RR, eds. Cancer Medicine. 6th ed. Ontário: Decker Inc; 2003. p. 2400.
3. Monzon J. CDKN2A mutations in multiple primary melanoma. N Engl J Med. 1998;338:879.
4. Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, et al. A natural history of melanoma and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer. 2002;94:3192.
5. Ross MH, Rowrell LJ. Histologia texto e atlas. 2nd ed. Baltimore: Panamericana; 1993.
6. Cotran R, Kumar V, Collins T. Robbins patologia estrutural e funcional. 6 ed. Rio de Janeiro. Guanabara Koogan; 2000.
7. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;182:572.
8. INCA [homepage]. 2005 Câncer de Pele Melanoma. [acesso 2005 ago 10]. Disponível em: http://www.inca.gov.br.
9. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin. 2003;53:5-26.
10. Katalinic A, Kunze U, Schafer T. Epidemiology of cuta neous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical sub types, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol. 2003;149:1200-6.
11. Wallon-Dumon G, Dreno B. The clinical diagnosis of melanoma. Presse Med. 2003;32:33-8.
12. Pinheiro AMC, Friedman H, Cabral ALSV, Rodrigues HA. Melanoma cutâneo: características clínicas, epidemiológicas e histopatológicas no Hospital Universitário de Brasília entre janeiro de 1994 e abril de 1999. An Bras Dermatol. 2003;78:179-86.
13. Lapa MS, Guedes KF, Schalch FO, Landman G. Melanomas malignos cutâneos tratados no Hospital de Cancer de São Paulo. Estudo retrospectivo para avaliação, fatores prognósticos e sobrevida. An Bras Dermatol. 2002;77:313-20.
14. Clemente C, Cook M, Ruiter D, Mihm MC. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol. 1991;22:313-9.
15. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19:3635-48.
16. Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1 mm thick). Cancer. 2004;100:433-4.
17. Scolyer RA, Thompson JF, Stretch JR, Sharma R, McCarthy SW. Pathology of melanocytic lesions: new, controversial, and clinically important issues. J Surg Oncol. 2004;86:200-11.
18. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in pacients with primary cutaneous melanoma: analysis of 3661 patients from a single center. Cancer. 2003;97:1488-98.
19. Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czemiechi B. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22:3668-76.
20. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Thin cutaneous malignant melanoma (< or = 1,5mm): identification of risk factors indicative of progression. Cancer. 1999;85:1067-76.
21. Veronese LA, Marques MEA. Critérios anatomopatoló gicos para melanoma maligno cutâneo: análise qualitativa de sua eficácia e revisão da literatura. J Bras Patol Med Lab. 2004;40:99-112.
22. Mckinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98:1223-31.
23. Balch CM, Soong SJ, Atkins M, Buzaid AC, Cascinelli N, Goit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54:131-49.
24. Edwood JM, Gallagher RP. Site distribution of malignant melanoma. Can Med Assoc J. 1983;128:1400.
25. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol. 2003;139:1620-4.
26. Lebwohl MG. Atlas de dermatologia e doenças sistêmicas. Rio de Janeiro: Revinter; 2000. p.190-8.